Dyslipidemia - Pipeline Review, H1 2018

  • ID: 4473102
  • Report
  • 306 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acasti Pharma Inc
  • BCWorld Pharm Co Ltd
  • CymaBay Therapeutics Inc
  • Gemphire Therapeutics Inc
  • Innovent Biologics Inc
  • Nippon Chemiphar Co Ltd
  • MORE
Dyslipidemia - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2018, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 25, 18, 13, 4, 40, 8 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 14 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acasti Pharma Inc
  • BCWorld Pharm Co Ltd
  • CymaBay Therapeutics Inc
  • Gemphire Therapeutics Inc
  • Innovent Biologics Inc
  • Nippon Chemiphar Co Ltd
  • MORE
Introduction

Dyslipidemia - Overview

Dyslipidemia - Therapeutics Development

Dyslipidemia - Therapeutics Assessment

Dyslipidemia - Companies Involved in Therapeutics Development

Dyslipidemia - Drug Profiles

Dyslipidemia - Dormant Projects

Dyslipidemia - Discontinued Products

Dyslipidemia - Product Development Milestones

Appendix

List of Tables:

Number of Products under Development for Dyslipidemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Dyslipidemia - Pipeline by Acasti Pharma Inc, H1 2018

Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H1 2018

Dyslipidemia - Pipeline by Amarin Corp Plc, H1 2018

Dyslipidemia - Pipeline by Amgen Inc, H1 2018

Dyslipidemia - Pipeline by Arisaph Pharmaceuticals Inc, H1 2018

Dyslipidemia - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2018

Dyslipidemia - Pipeline by AstraZeneca Plc, H1 2018

Dyslipidemia - Pipeline by BCWorld Pharm Co Ltd, H1 2018

Dyslipidemia - Pipeline by Bioleaders Corp, H1 2018

Dyslipidemia - Pipeline by BioRestorative Therapies Inc, H1 2018

Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2018

Dyslipidemia - Pipeline by Cadila Healthcare Ltd, H1 2018

Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd, H1 2018

Dyslipidemia - Pipeline by Cardax Inc, H1 2018

Dyslipidemia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2018

Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H1 2018

Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Dyslipidemia - Pipeline by CJ HealthCare Corp, H1 2018

Dyslipidemia - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2018

Dyslipidemia - Pipeline by CymaBay Therapeutics Inc, H1 2018

Dyslipidemia - Pipeline by Daewon Pharm Co Ltd, H1 2018

Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Dyslipidemia - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Dyslipidemia - Pipeline by Eli Lilly and Co, H1 2018

Dyslipidemia - Pipeline by Esperion Therapeutics Inc, H1 2018

Dyslipidemia - Pipeline by Gemphire Therapeutics Inc, H1 2018

Dyslipidemia - Pipeline by Gilead Sciences Inc, H1 2018

Dyslipidemia - Pipeline by Golden Biotechnology Corp, H1 2018

Dyslipidemia - Pipeline by HanAll Biopharma Co Ltd, H1 2018

Dyslipidemia - Pipeline by Handok Inc, H1 2018

Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2018

Dyslipidemia - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2018

Dyslipidemia - Pipeline by Innovent Biologics Inc, H1 2018

Dyslipidemia - Pipeline by InStar Technologies AS, H1 2018

Dyslipidemia - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018

Dyslipidemia - Pipeline by JW Pharmaceutical Corp, H1 2018

Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co Ltd, H1 2018

Dyslipidemia - Pipeline by Kowa Co Ltd, H1 2018

Dyslipidemia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2018

Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Dyslipidemia - Pipeline by Lipigon Pharmaceuticals AB, H1 2018

Dyslipidemia - Pipeline by LipimetiX Development Inc, H1 2018

Dyslipidemia - Pipeline by Nippon Chemiphar Co Ltd, H1 2018

Dyslipidemia - Pipeline by NorthSea Therapeutics BV, H1 2018

Dyslipidemia - Pipeline by Omeros Corp, H1 2018

Dyslipidemia - Pipeline by Pharmena SA, H1 2018

Dyslipidemia - Pipeline by Protalix BioTherapeutics Inc, H1 2018

Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Dyslipidemia - Pipeline by Samjin Pharm Co Ltd, H1 2018

Dyslipidemia - Pipeline by Sancilio & Company Inc, H1 2018

Dyslipidemia - Pipeline by SJT Molecular Research SL, H1 2018

Dyslipidemia - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Dyslipidemia - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2018

Dyslipidemia - Pipeline by Viking Therapeutics Inc, H1 2018

Dyslipidemia - Pipeline by Yuhan Corp, H1 2018

Dyslipidemia - Dormant Projects, H1 2018

Dyslipidemia - Dormant Projects, H1 2018 (Contd..1), H1 2018

Dyslipidemia - Dormant Projects, H1 2018 (Contd..2), H1 2018

Dyslipidemia - Dormant Projects, H1 2018 (Contd..3), H1 2018

Dyslipidemia - Dormant Projects, H1 2018 (Contd..4), H1 2018

Dyslipidemia - Dormant Projects, H1 2018 (Contd..5), H1 2018

Dyslipidemia - Dormant Projects, H1 2018 (Contd..6), H1 2018

Dyslipidemia - Dormant Projects, H1 2018 (Contd..7), H1 2018

Dyslipidemia - Dormant Projects, H1 2018 (Contd..8), H1 2018

Dyslipidemia - Dormant Projects, H1 2018 (Contd..9), H1 2018

Dyslipidemia - Discontinued Products, H1 2018

Dyslipidemia - Discontinued Products, H1 2018 (Contd..1), H1 2018

Dyslipidemia - Discontinued Products, H1 2018 (Contd..2), H1 2018

Dyslipidemia - Discontinued Products, H1 2018 (Contd..3), H1 2018

List of Figures:

Number of Products under Development for Dyslipidemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acasti Pharma Inc
  • Akcea Therapeutics Inc
  • Amarin Corp Plc
  • Amgen Inc
  • Arisaph Pharmaceuticals Inc
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • BCWorld Pharm Co Ltd
  • Bioleaders Corp
  • BioRestorative Therapies Inc
  • Boryung Pharmaceutical Co Ltd
  • Cadila Healthcare Ltd
  • Cadila Pharmaceuticals Ltd
  • Cardax Inc
  • Catabasis Pharmaceuticals Inc
  • Cerenis Therapeutics Holding SA
  • Chong Kun Dang Pharmaceutical Corp
  • CJ HealthCare Corp
  • Connexios Life Sciences Pvt Ltd
  • CymaBay Therapeutics Inc
  • Daewon Pharm Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Eli Lilly and Co
  • Esperion Therapeutics Inc
  • Gemphire Therapeutics Inc
  • Gilead Sciences Inc
  • Golden Biotechnology Corp
  • HanAll Biopharma Co Ltd
  • Handok Inc
  • Hyundai Pharmaceutical Co Ltd
  • Ildong Pharmaceutical Co Ltd
  • Innovent Biologics Inc
  • InStar Technologies AS
  • Jeil Pharmaceutical Co Ltd
  • JW Pharmaceutical Corp
  • Kotobuki Pharmaceutical Co Ltd
  • Kowa Co Ltd
  • Kuhnil Pharmaceutical Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lipigon Pharmaceuticals AB
  • LipimetiX Development Inc
  • Nippon Chemiphar Co Ltd
  • NorthSea Therapeutics BV
  • Omeros Corp
  • Pharmena SA
  • Protalix BioTherapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • Samjin Pharm Co Ltd
  • Sancilio & Company Inc
  • SJT Molecular Research SL
  • Takeda Pharmaceutical Co Ltd
  • Tasly Pharmaceutical Group Co Ltd
  • Viking Therapeutics Inc
  • Yuhan Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll